Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alto Neuroscience Inc.
Headquarters: Los Altos, CA, United States of America
Website: https://www.altoneuroscienc...
Year Founded: 2019
Status: Public
Industry Sector: HealthTechnology
CEO: Amit Etkin, MD, PhD
Number Of Employees: 76
Enterprise Value: $-47,218,540
PE Ratio: -0.9
Exchange/Ticker 1: NYSE:ANRO
Exchange/Ticker 2: N/A
Latest Market Cap: $54,685,600
BioCentury | Jan 31, 2025
Product Development
Precision neuropsychiatry spotlight: a BioCentury podcast
Plus: Insights from Icon’s Peter Schueler on the ECNP Roadmap Meeting on Precision Psychiatry
BioCentury | Sep 4, 2024
Discovery & Translation
The inextricable linkage of biomarkers and target discovery
Back to School 2024: How biomarkers can help validate targets while bringing precision medicine to I&I and neurology
BioCentury | Sep 3, 2024
Discovery & Translation
Neurology’s human data revolution
Back to School 2024 looks at how neuroscience companies are reducing to practice the concept of human-first discovery
BioCentury | Sep 3, 2024
Discovery & Translation
Eyes on the target: Drug discovery’s new paradigm
Back to School 2024: Can biotech write a more successful playbook for translating from target to product?
BioCentury | May 30, 2024
Product Development
Clinical Report: Phase III win for J&J in neuropsychiatry; Biohaven falls on BHV-1300 data
Plus: Insmed gets boost from bronchiectasis readout and updates from HI-Bio, Corcept, Tango and Ikena
BioCentury | May 22, 2024
Management Tracks
Eden Wells to lead insights and decision science at Novartis
Plus: Nurix appoints Julia Gregory as chair, and updates from Valneva, Alto, Cour and Kronos
BioCentury | Feb 10, 2024
Finance
Year’s start mostly strong for biotech IPOs
Four of six companies to go public on U.S. exchanges post positive aftermarket moves
BioCentury | Feb 6, 2024
Product Development
BMS’s patent cliff challenge, and Congress targets China biotech: BioCentury’s latest podcast
Plus: IPO sentiment and the innovation behind 2023’s series A companies
BioCentury | Feb 2, 2024
Finance
Public equity roundup: Alto, Fractyl price IPOs, Vaxcyte raises $750M
Plus: Kyverna lining up a listing next week, and PIPEs for Tectonic, Tyra and Arcus
BioCentury | Jan 31, 2024
Product Development
The path to precision neuropsychiatry: J&J’s perspective
From subjective symptoms to objective metrics to biological signatures, neuroscience head Bill Martin paints a trajectory of psychiatry’s path ahead
Items per page:
1 - 10 of 25